anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Sparkline

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 22,963
Current window 15,661-15,690
Pages 766
Rows per page 30
Arc: Sparklineclear collectionreset all
18 30 60

Arc

15,661-15,690 of 22,963

filter-aware
40
The slide includes a disclaimer at the bottom regarding FDA clearance.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
41
The slide uses a table to validate performance against industry-standard benchmarks.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
42
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
43
Slide 32 from a Theranos presentation deck.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
44
References CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
45
The slide includes a disclaimer about FDA clearance status and definitions for (L) and (H) samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
46
The slide outlines the clinical study parameters for a Herpes diagnostic test.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
47
Includes FDA clearance references and disclaimer.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
48
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
49
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
50
The slide outlines a four-step laboratory workflow involving staining, lysis/fixation, loading, and algorithmic analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
51
This slide is from the Theranos deck, illustrating their proprietary image processing pipeline.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
52
References CLSI EP05-A3 standard for precision performance testing.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
53
Includes FDA disclaimer and definitions for (L) and (N) cell counts.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
54
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
55
The slide presents method comparison data (regression analysis) for three different cell types, including statistical metrics like r-squared, median bias, and Allowable Total Error (ATE).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
56
The slide shows three scatter plots with regression lines, R-squared values, and performance metrics (bias, ATE, TE).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
57
Includes technical definitions of error metrics and regulatory disclaimers.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
58
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
59
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
60
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
61
The slide compares the assay's LoD (480 copies/mL) against the CDC Zika test LoD (930 copies/mL).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
62
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
63
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
64
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
65
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
66
The slide presents experimental validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
67
Includes a standard Theranos FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
68
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
69
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit